Disc Medicine announced its Q1 2026 financial results, highlighting the completion of enrollment for its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP), with topline data expected in Q4 2026. The company also plans to present updated Phase 2 data for DISC-0974 in myelofibrosis anemia at the ASCO meeting and expects data from ongoing studies of DISC-3405 in polycythemia vera and sickle cell disease by Q4 2026. Disc Medicine ended Q1 with $730 million in cash, supporting operations into 2029. These milestones position the company for multiple important catalysts later this year.
RBC Capital initiated coverage on Atlassian with an Outperform rating, highlighting its strong position in the $67 billion collaboration software market and rapid AI advancements through its Rovo AI assistant. Atlassian's Q4 fiscal 2026 results excee...
Zoom Video Communications reported better-than-expected Q2 earnings with an EPS of $1.55 and revenue of $1.28 billion, marking a 4.9% year-over-year increase. The growth was mainly fueled by its enterprise segment, which saw revenue rise 7.8% to $787...
UP Fintech Holding Limited will announce its Q2 2026 financial results on August 26, 2026, with analysts expecting an EPS of $0.21 and revenues around $153.93 million. The company shows strong financial health, including a low debt-to-equity ratio of...
Chatham Lodging Trust (CLDT) has seen its share price rise 73% since March, outperforming other hotel REITs. The company raised its AFFO guidance to $1.28–$1.34 per share, driven by strong Q2 results, margin expansion, and record revenue per availabl...
Waystar has appointed Amit Khanna as Chief Product and Technology Officer and Todd Woods as Chief Commercial Officer to accelerate innovation and growth in healthcare payment software. Khanna brings over 25 years of tech experience, including leaders...
